ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
Noninvasive and Sensitive Biosensor for the Detection of Oral Cancer Prognostic Biomarkers.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Artificial Intelligence in Electrochemical Sensing: A Network Evidence Map of Translational Barriers and Pathways to Point-of-Care Deployment.Biosensors · 2026Review
- Electrochemical Biosensing Strategies for Oral Health: From Engineered Interfaces to Advanced Transistor Architectures.Advanced healthcare materials · 2026Review
- Fibronectin Is a Likely Therapeutic Target Shared by Oral and Breast Carcinomas.International journal of molecular sciences · 2026Article
- Noninvasive and Sensitive Biosensor for the Detection of Oral Cancer Prognostic Biomarkers.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Artificial Intelligence-Assisted Nanosensors for Clinical Diagnostics: Current Advances and Future Prospects.Biosensors · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Early detection of oral squamous cell carcinoma (OSCC) significantly enhances treatment outcomes and survival rates, with lymph node metastasis serving as a main prognostic factor. However, current clinical practices rely on TNM classification, including histological confirmation of metastatic disease in lymph nodes, often involving elective neck dissection, a procedure that can cause post-operative morbidity. Here it is shown that zinc imidazole framework-8 (ZIF-8) electrochemical biosensors can effectively distinguish non-metastatic (N0) from lymph node metastatic (N+) OSCC saliva samples. By monitoring the OSCC biomarkers cystatin B (CSTB), leukotriene A 4 hydrolase (LTA4H), and collagen type VI alpha 1 chain (COL6A1) in human saliva through electrochemical impedance spectroscopy and antigen-antibody immunoreactions, elevated biomarker levels in N0 samples are observed. The biosensor displays high accuracy, specificity, and reproducibility, with limits of detection lower than 0.4 ng mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.